Nuvilex, Inc. (OTCQB: NVLX) employs a live-cell encapsulation technology, which is a way to enclose living cells in protective “cocoons” about the size of the head of a pin - the company does not encapsulate drugs, but living cells. Each capsule can enclose approximately 10,000 cells; this number can differ depending upon the size of the cells encapsulated. The cell encapsulation technology used by Nuvilex can be classified as a “platform” upon which treatments for different indications may be built. Depending on the type of cells used, the encapsulated cells can be employed in developing treatments for serious, debilitating and even deadly diseases. Nuvilex’s primary interests in the use of the live-cell encapsulation technology are for the development of treatments for various cancers and for diabetes. SNNLive spoke with Kenneth Waggoner, President and CEO of Nuvilex, Inc. at the 3rd Annual Marcum MicroCap Conference 2014 in New York City, NY.
Mr. Waggoner begins with an overview of the company, “Nuvilex is a biotech company that has a platform technology, it’s a delivery system referred to as ‘cell-in-the-box’. It’s a live-cell encapsulation technology that we’ll use to treat solid tumors in particular pancreatic cancer tumors and diabetes.” This encapsulation technology works by having, “cells that have been specifically designed to overexpress a particular enzyme that will change that pro-drug from its inert system into a cancer killing form,” explains Mr. Waggoner.
“What’s unique about this encapsulation technology that we have is that you can use these capsules to encapsulate any kind of cell line enormous results, positive results on cancer,” concludes Mr. Waggoner. For more information, check out their website at www.nuvilex.com.
© 2017 Stock News Now
Supported by Superior Web Solutions